Lacosamide G.L. Pharma Gmbh

Lacosamide, the active ingredient in Lacosamide G.L. Pharma Gmbh, is an anti‑epileptic presented as an intravenous formulation for intravenous use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, providing seizure‑control benefits as part of a comprehensive management plan.

GNH USA supplies Lacosamide G.L. Pharma Gmbh as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide with adherence to quality standards and regulatory requirements across multiple regions and supporting timely logistics.

Lacosamide is an anti‑epileptic medication used in the management of seizure disorders.

Partial‑onset seizures (focal onset): Reduces seizure frequency in patients with epilepsy. Adjunctive therapy for refractory focal seizures: Enhances seizure control when added to existing antiepileptic regimen. Focal seizures in adults: Provides an additional option for adult patients with uncontrolled focal seizures. Focal seizures in pediatric patients: Used as part of treatment plan for children with focal epilepsy. Epilepsy with comorbid conditions: Offers an alternative mechanism for patients who have not responded to other sodium channel blockers.

Lacosamide may cause a range of adverse reactions, from mild, transient symptoms to potentially serious events that require medical attention.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Fatigue: unusual tiredness or lack of energy. - Headache: mild to moderate head pain. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - PR interval prolongation: cardiac conduction delay observable on ECG. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive mood or suicidal ideation. These events are rare but may be life‑threatening and require immediate medical evaluation. These effects are generally reversible upon discontinuation or dose adjustment.

When using lacosamide, certain precautions should be observed to ensure patient safety. - Renal impairment: dose may need adjustment and renal function should be monitored. - Hepatic impairment: consider dose reduction and monitor liver enzymes. - Cardiac conduction: baseline ECG recommended; monitor for PR interval changes. - Pregnancy: category C; use only if benefits outweigh potential risks. - Concomitant anti‑epileptics: monitor for additive CNS effects and adjust doses as needed. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide plasma levels and effectiveness. - Drugs that prolong PR interval (e.g., class Ia antiarrhythmics): increase risk of cardiac conduction abnormalities. - Concurrent use with other sodium‑channel blockers: may enhance central nervous system depression.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: may require dose adjustments to maintain seizure control. - Alcohol: can increase dizziness and sedation when combined with lacosamide. - Hormonal contraceptives: lacosamide may reduce contraceptive efficacy; alternative methods should be considered.